Online webinar: Rational malaria vaccine design with high-density peptide arrays

MalariaAn efficacious and practicable vaccine conferring sterile immunity towards a Plasmodium infection is still not available. A crucial factor for the impact of a given anti-plasmodial subunit vaccine is the identification of the most potent parasitic components required to induce protection from both infection and disease. High-density peptide arrays can be used to identify novel immunogenic antibody epitopes under a large number of potential antigens/peptides. Ultimately, discovered antigen candidates and/or epitope sequences can be translated into vaccine prototype design.

 

About the Presenter

Dr. Kirsten Heiss, MalVa GmbHKirsten Heiss graduated from Ruprecht-Karls University Heidelberg in 2006. She did her Ph.D. in infectious diseases working on the malaria-causing agent Plasmodium. Further Postdoc studies at the Institute of Immunology at University Hospital Hamburg-Eppendorf enabled her to acquire profound knowledge in infection-immunological questions and immunological methodologies. In 2009, the development of a novel next-generation malarial subunit vaccine started at the University Hospital Heidelberg. Since May 2011, Dr. Kirsten Heiss is managing director of MalVa GmbH, supported by MalVa’s advisors and scientific team.

 

Watch here: Employing high-density peptide arrays for rational vaccine design in malaria